Trials Sponsors Conditions Drugs Pricing

Conditions

Healthy

Keywords

prazosindopaminehealthyPositron Emission TomographyPHNOscaneffect

Outcome Measures

Primary Outcomes (1)

Changes in [11C]-(+)-PHNO Binding (Measured as Binding Potential) in Dorsal Caudate (DC)
Binding potential (an estimate of the ratio of Bmax/kd) was measured by positron emission tomography to determine if taking prazosin alters the amount of tracer bound to receptors. A negative change in binding potential means a decrease in binding potential and a positive change in binding potential represents an increase. Bmax is the total density of receptors. kd is the affinity of a drug for the target
3 weeks after taking prazosin

Study Arms (1)

Prazosin Hydrochloride

EXPERIMENTAL

Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.

Drug: Prazosin Hydrochloride

Interventions

Prazosin HydrochlorideDrug

Gradual upward titration to 15mg/day for approximately three weeks.

Also known as: Teva-Prazosin, Prazosin, Minipress

Prazosin Hydrochloride

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age19 Years - 45 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Healthy males and females of any ethnic origin between 19 and 45 years old

You may not qualify if:

Sponsors & Collaborators

Ontario Lung Association
Othercollaborator
Pfizer
Industrycollaborator
Centre for Addiction and Mental Health

Study Sites (1)

Centre for Addiction and Mental Health

Toronto, Ontario, M5T 1R8, Canada

MeSH Terms

Interventions

Prazosin

Intervention Hierarchy (Ancestors)

QuinazolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Results Point of Contact

Title: Bernard Le Foll
Organization: Centre for Addiction and Mental Health

Study Officials

Bernard Le Foll, MD, PhD
Centre for Addiction and Mental Health
PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee: No
Restrictive Agreement: No

Enrollment

20 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NA
Masking: NONE
Purpose: BASIC SCIENCE
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

November 26, 2013

First Posted

December 3, 2013

Study Start

November 2013

Actual (reported)

The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Prazosin Hydrochloride

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

Data Sharing

Available IPD Datasets

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Prazosin Hydrochloride

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

Data Sharing

Available IPD Datasets

Source record

Locations